# Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

> **NCT05835687** · PHASE1 · RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Central Nervous System Neoplasms
- Atypical Teratoid/Rhabdoid Tumor
- Diffuse Midline Glioma, H3 K27M-Mutant
- Ependymoma
- High Grade Glioma
- Glioblastoma
- Medulloblastoma

## Interventions

- **DRUG:** B7-H3-CAR T cells

## Key facts

- **NCT ID:** NCT05835687
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-27
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05835687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05835687, "Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05835687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*